MX2018011986A - Analogos de eicosanoides de cyp para su uso en el tratamiento o la prevencion de un trastorno asociado a neovascularizacion y/o a inflamacion. - Google Patents

Analogos de eicosanoides de cyp para su uso en el tratamiento o la prevencion de un trastorno asociado a neovascularizacion y/o a inflamacion.

Info

Publication number
MX2018011986A
MX2018011986A MX2018011986A MX2018011986A MX2018011986A MX 2018011986 A MX2018011986 A MX 2018011986A MX 2018011986 A MX2018011986 A MX 2018011986A MX 2018011986 A MX2018011986 A MX 2018011986A MX 2018011986 A MX2018011986 A MX 2018011986A
Authority
MX
Mexico
Prior art keywords
neovascularization
inflammation
treating
preventing
eicosanoids
Prior art date
Application number
MX2018011986A
Other languages
English (en)
Inventor
MÜLLER Dominik
Fischer Robert
Konkel Anne
Wesser Tim
Hagen SCHUNCK Wolf
Lossie Janine
Original Assignee
Omeicos Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeicos Therapeutics Gmbh filed Critical Omeicos Therapeutics Gmbh
Priority claimed from PCT/EP2017/057830 external-priority patent/WO2017168007A1/en
Publication of MX2018011986A publication Critical patent/MX2018011986A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se refiere a compuestos de acuerdo con la fórmula general (I) que son análogos metabólicamente fuertes de mediadores lipídicos bioactivos derivados de ácidos grasos poliinsaturados omega-3 (PUFA n-3) para su uso en el tratamiento o la reducción del riesgo de desarrollar o prevenir: (i) neovascularización y/o (ii) un trastorno inflamatorio, en particular, trastornos oftálmicos asociados a neovascularización y/o inflamación.
MX2018011986A 2016-04-01 2017-04-03 Analogos de eicosanoides de cyp para su uso en el tratamiento o la prevencion de un trastorno asociado a neovascularizacion y/o a inflamacion. MX2018011986A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662317253P 2016-04-01 2016-04-01
EP17153412 2017-01-26
PCT/EP2017/057830 WO2017168007A1 (en) 2016-04-01 2017-04-03 Analogs of cyp-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation

Publications (1)

Publication Number Publication Date
MX2018011986A true MX2018011986A (es) 2019-07-10

Family

ID=65863570

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011986A MX2018011986A (es) 2016-04-01 2017-04-03 Analogos de eicosanoides de cyp para su uso en el tratamiento o la prevencion de un trastorno asociado a neovascularizacion y/o a inflamacion.

Country Status (4)

Country Link
US (2) US20190117597A1 (es)
JP (1) JP6944465B2 (es)
CN (1) CN109562083A (es)
MX (1) MX2018011986A (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2208720A1 (en) * 2009-01-13 2010-07-21 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Novel eicosanoid derivatives
CA2832422C (en) * 2011-04-06 2020-07-28 Mcw Research Foundation, Inc. Epoxyeicosatrienoic acid analogs and methods of making and using the same
CN110950786A (zh) * 2014-01-22 2020-04-03 分子医学马克斯德尔布吕克中心 新型cyp-类二十烷酸衍生物

Also Published As

Publication number Publication date
US20190117597A1 (en) 2019-04-25
RU2018133413A (ru) 2020-05-12
JP6944465B2 (ja) 2021-10-06
NZ746544A (en) 2021-10-29
RU2018133413A3 (es) 2020-05-12
CN109562083A (zh) 2019-04-02
US20210353569A1 (en) 2021-11-18
JP2019515887A (ja) 2019-06-13

Similar Documents

Publication Publication Date Title
MY165048A (en) Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
MX2016008270A (es) Lipido que comprende acidos grasos poliinsaturados de cadena larga.
EA201400152A1 (ru) Микроорганизмы, продуцирующие эйкозапентаеновую кислоту, композиции, содержащие жирные кислоты, и способы их получения и применения
IL262348A (en) Preparations for the treatment of excessive radiation disorders
GEP201606568B (en) Compositions for the treatment of neurologic disorders
EP3579830A4 (en) Fatty acid formulations containing cannabis for the treatment of diseases of the nervous system
MX2018000847A (es) Analogos metabolicamente robustos de cyp-eicosanoides para el tratamiento de enfermedades cardiacas.
MA43532A (fr) Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques
CY1123942T1 (el) Συνθεσεις ωμεγα-3 λιπαρων οξεων για τη θεραπεια ασθενειων που επιφερουν βλαβη στο νευρικο συστημα
MA40417A (fr) Mélange d'acides gras et de palmitoyl éthanolamide pour utilisation dans le traitement de pathologies inflammatoires et allergiques
EA201791885A1 (ru) Смесь жирных кислот и её применение для лечения воспалительных патологий
MX2021008819A (es) Analogos de cisteamina resistentes a la ado y sus usos.
MX2016009507A (es) Derivados de citocromo p450 (cyp)-eicosanoide novedosos.
PH12017500988A1 (en) Calcitonin analogues for treating diseases and disorders
BR112018070194A2 (pt) composto e composição para uso
IN2014DN05811A (es)
MX2018011986A (es) Analogos de eicosanoides de cyp para su uso en el tratamiento o la prevencion de un trastorno asociado a neovascularizacion y/o a inflamacion.
PH12017500738A1 (en) Feeding algae to cattle at low doses to produce high omega 3 levels in beef
PL3560342T3 (pl) Kompozycje wielonienasyconych kwasów tłuszczowych wzbogacone w dha
EA201692398A1 (ru) Гомогенная композиция для перорального введения, содержащая омега-3 полиненасыщенные жирные кислоты и ресвератрол
EP3370714A4 (en) COMPOSITIONS AND METHODS FOR TREATING FATTY ACID METABOLISM DISORDERS
MX2016013680A (es) Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos.
MX2016016118A (es) Métodos de tratamiento de enfermedades y trastornos del neurodesarrollo.
MX2022005627A (es) Lipido que comprende acido docosapentaenoico.
EP4327870A3 (en) Method for improving white matter integrity in hyperphenylalaninemia and phenylketonuria patients